

BIOMARKERS AND TOXICITY MECHANISMS 01 - INTRODUCTION

Luděk Bláha, PřF MU, RECETOX www.recetox.cz

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.









Course summary

1) Introduction

- Intro and overview of the mechanisms beyond the toxicity (with special respect to environmental contaminants)
- Intro and concept of biomarkers

2) Details on selected important toxicity mechanisms

- Membrane toxicity, enzyme inhibitions, oxidative stress, genotoxicity, Nuclear Receptors (AhR, ER, AR) etc.
- Methods to determine toxicity mechanism

3) Biomarkers

- What it is and how to find (identify) suitable biomarker(s)?
- The overview of the most important biomarker classes
- Methods of biomarker assessment




The importance of understanding to toxicity mechanisms



1962








© Patuxent Wildlife Refuge, MA, USA







CHEMICALS 97 Years' Service to Industry . Farm . Home

PENNSYLVANIA SALT MANUFACTURING COMPANY WIDENER BUILDING, PHILADELPHIA 7, PA.

Knoxfor industry—Food off processing plants, laun-dries, dry cleaning plants, botels . . . dozens of industries

gain effective bug control, more pleasant work conditions with Pennsalt DDT products,

In vivo: shell thinning










Biochemistry discovered in 1970s: **Bird** carbonate dehydratase

Bitman et al. Science 1970, 168(3931): 594




In situ: bioaccumulation -> bird population decline



CI CI

Thalidomide



- Originally marketed in 1957 as sedative / hypnotic
 - also curing anxiety, gastritis, tension
 - against nausea and morning sickness of pregnant
 - TERATOGENICITY → Develoment of phocomelia = limb malformations (10 000 children worldwide / 40% survived)







	Teratogenic Manifestations of Thalidomide																				
	Number of Days Past Last Menstruation																				
	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
Ear missing (anotia)																					
Thumbs missing or deformed (aplasia)																					
One or both arms missing (amelia)																					
Both arms shortened (phocomelia)																					
Hip dislocation																					
Ears deformed																					
Legs Missing (amelia)																					
Both Legs shortened (phocomelia)																					
Thumbs malformed (triphalangism)																					
Humerus missing or deformed (ectromelia)																					
Femur missing or deformed (ectromelia)																					

Currently still in use - completely different targets
 : anticancer (multiple myeloma), antileprosis, immunosupression



Thalidomide








Thalidomide

... mechanisms of action


(1) Sedative effects

... mechanism unknown

(2) Teratogenicity




(3) Anticancer




MECHANISMS of chronic toxicity

Various chronic effects have uniform biochemical basis



- principle studies with mechanistically based in vitro techniques
- estimation of in vitro effects of individual compounds

Understanding MoA ... may predict higher-level effects







Basics and keywords from toxicology



Toxicity - concept




Figure 1 The effective concentration of a pollutant in an organism (e.g. fish, daphnia, algae) or at the target site inside the organism is the link between the environmental fate of a pollutant and its toxic effect.




From mechanisms (or modes of action) to biomarkers

- Chemical enters organism
 + may be metabolized/detoxified,
 transported, released ...
- → Toxicokinetics

- Chemical reacts with target (e.g. DNA) and changes a specific nucleotide (e.g. G → de-oxo-G)
- Toxicodynamics
 = toxicity mechanisms
 (MoA) and following toxic
 effects (e.g. mutation,
 cancer ...)

Elevated de-oxo-G in blood



 → (Selective) biochemical marker (biomarker)
 = information about exposure and/or effect

Toxicity – the cause-effect paradigm

Paracelsus (1493 - 1541)




'What is there which is not a poison?

- All things are poison and nothing without poison.
- Solely <u>the dose determines</u> that a thing is not a poison.
- Toxicology the science of doses



What processes are beyond toxicokinetics?



Toxicokinetics ...

... EXPOSURE phase -> Determines the final dose



Toxicokinetics in fish





Fig. 3.5 Uptake, accumulation and loss processes for a toxicant in the ambient water with fish.



ToxicoDYNAMICS



toxických látek v prostředí

What is toxicity? What are the types of effects?

Toxicity

degree to which a substance (at certain dose) can damage an organism

Exposure & toxicity

- acute (immediate, high doses, days)
- chronic (sublethal / low doses, long-term)

Effect & toxicity

- lethal (acute)
 - mortality definitive endpoint / high doses
 - easy to determine (single endpoint death)
- nonlethal, sublethal (chronic)
 - endocrine disruption, reproduction toxicity, immunotoxicity, tumor induction etc.
 - difficult to determine (multiple endpoints)
 - more specific low concentrations / longer exposures
 - often reflected by specific biochemical changes (biomarkers)

Systems and organ & toxicity

- Systemic lethal toxicity
- Organ-specific toxicity (neurotoxicity, hepatotoxicity, nefrotoxicity ...)
- Developmental toxicity
- Reproduction toxicity




Principles of toxicity testing

- 1) Define and know **biological target** (molecule, cell, organism, population) and its properties
- 2) Define and know chemical and its properties
- 3) Define exposure of biological system to a chemical
 - variable concentrations
 - defined or variable duration (time)
 - conditions (T, pH, life stage)
- 4) Assess effects, i.e. Changes in measurable parameter in relationship to variable doses
- 5) Dose-response evaluation & estimation of the toxicity value (i.e. concentration or dose): LDx, ICx, ECx, LOEC/LOEL, MIC ...



Effect assessment - procedure









How to study (chronic) toxicity?

- In vitro studies (biochemical mechanisms)
 - + easy to perform, short-term
 - + highly controlled conditions
 - + lower amounts of chemicals needed (new cmpnds screening)

- ecotoxicological relevancy
- mostly with vertebrate cells

- In vivo biotest testing
 - + unique whole organisms
 - + controlled conditions
 - + better ecological interpretation

- only few (ecologically nonrelevant) organisms used
- mostly ACUTE assays
- chronic: long exposures
- Field and in situ observations, epidemiological studies



Hazard assessment

Traditionally – Evaluation of adverse effects using the whole organism models





Hazard assessment

Traditionally – Evaluation of adverse effects using the whole organism models



New – Ex vivo / in vitro / In chemico / In silico Methods




Chemical-biological interactions, Mechanistic Toxicological Data




10⁴ Chemicals

Mode of Action (omics) toxicity testing



Omes is not only for humans ...



MoA and omics are supported by strategic documents & organizations

Toxicity Testing in the 21st Century: A Vision and a Strategy

US National Academies of Sciences http://www.nap.edu/catalog/11970.html



LEARN THE ISSUES | SCIENCE & TECHNOLOGY | LAWS & REGULATIONS | ABOUT E

Computational Toxicology Research

You are here: EPA Home » Research & Development » CompTox » ToxCast™

Key Links


CompTox Home Basic Information Organization


Research Projects Chemical Databases CompTox Events

ToxCast™

Screening Chemicals to Predict Toxicity Faster and Better








Hazard assessment


Traditionally – Evaluation of adverse effects using the whole organism models



Key task/question:

How to link MECHANISTIC INFORMATION with APICAL ENDPOINTS?


Adverse Outcome Pathways



The **EXISTING KNOWLEDGE** is used **to link the** two anchor points: **Molecular Initiating Event** (MIE) and **Adverse Outcome** (AO) **via a series** of intermediate steps: **Key Events**

Ankley, G. T., R. S. Bennett, et al. (2010) "Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment." <u>Environmental Toxicology and Chemistry</u> **29**(3): 730-741.

Concept of "Adverse Outcome Pathway" (AOP)





AOP = Global strategy with support from OECD, EU, USA



OECD Home > Chemical safety and biosafety > Testing of chemicals > Adverse Outcome Pathways, Molecular Screening and Toxicogenomics

> Testing of chemicals	Adve
> Assessment of chemicals	Toxio
> Risk management of chemicals	
> Chemical accident prevention, preparedness and response	WHAT'S
> Pollutant release and transfer register	SURVEY (
> Safety of manufactured nanomaterials	feedback o to identify v
> Agricultural pesticides and biocides	The survey However, s
> Biosafety - BioTrack	

rse Outcome Pathways, Molecular Screening and cogenomics

NEW

ON ADVERSE OUTCOME PATHWAYS (AOPS) TO IDENTIFY DEVELOPMENT PRIORITIES

has launched a survey to explore the utility of AOPs for regulatory assessment of chemicals and to identify development priorities. The objective is to collect on how the AOP concept and/or existing AOPs are already being used for regulatory purposes, to understand where they fall short regarding their utility, and what directions and priorities future AOP development work should embrace to increase their impact on regulatory toxicology and chemical risk assessment.

is mainly for chemical safety regulators who are experiencing a transition in their work towards an increased use of 'alternative' methods and AOPs. stakeholders that come from the regulated community and environmental NGOs are also welcome to participate.


vey is now closed. Thank you for your submissions.

http://www.oecd.org/chemicalsafety/testing/projects-adverse-outcome-pathways.htm



Adverse Outcome Pathway Knowledge Base (AOP-KB)

AOP-KB || Background || How to contribute



Please click on any of the AOP-KB elements you want to use.

Please note that the AOP-KB is work in progress and more elements will become available over time.









http://aopkb.org/

Key documents

OECD Guidance document and a template for developing and assessing adverse outcome pathways (Series No. 184, Series on Testing and Assessment)

Handbook for AOP developers

AOP Wiki

- https://aopkb.org/aopwiki/index.php/Main_Page
- Wiki-based platform for development of AOPs
- Only members of an OECD AOP development project can create / edit AOPs















What AOPs are now in AOP Wiki (July 2017)?













OECD Endorsed (WNT and TFHA)	6	 Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations Aromatase inhibition leading to reproductive dysfunction
EAGMST Approved	1	 Androgen receptor agonism leading to reproductive dysfunction
EAGMST Under Review & for comments	18	
EAGMST Under Development	84	
SAAOP AOP Under Development	130+	

- OECD Extended Advisory Group on Molecular Screening and Toxicogenomics (EAG MST)
- The Working Group of the National Coordinators of the Test Guidelines Programme (WNT)



AOP Example: MIE aromatase inhibition




Fig. 3. An adverse outcome pathway in fish [2,50]. Aromatase inhibitor example. (A) Aromatase inhibition by fadrozole; (B) Reduction in circulating estradiol; (C) Reduction in circulating vitellogenin (Vtg); (D) Histopathology of ovarian tissue, top panel normal ovary, bottom panel fadrozole treated; note oocyte atresia; (E) Adverse outcome on egg production–fecundity (\bigcirc Elsevier, Used with permission,)


Environmental Toxicology and Chemistry, Vol. 30, No. 1, pp. 64-76, 2011



Aromatase inhibition leading to reproductive dysfunction (in fish)

https://aopwiki.org/wiki/index.php/Aop:25


v prostředí



MIE:1

KE:2

AOP Example from RECETOX: Modulation of RAR/RXR → developmental toxicity in fish






Activation of RAR/RXR

in P19/A15 cells by atRA and cyanobacterial metabolites

atRA

other RAs in cyanos





ZF exposed to ATRA and cyanobacterial (120 hpf) - Control (A), exudates of C. raciborskii 3.3 (B) and 10 (C), M. aeruginosa 10 (D) and D. quadricaudatus 17 (E). ATRA 4 µg/L (13.3 nM) (F), 12 μ g/L (40 nM) ((G) and (H)), 36 μ g/L (I) and 108 μ g/L (J).


> Jonáš et al. 2014 Aquatic Toxicology http://dx.doi.org/10.1016/j.aguatox.2014.06.022


Kidd, K.A. et al. 2007. <u>Collapse of a fish population</u> following exposure to <u>a synthetic estrogen</u>. *Proceedings of the National Academy of Sciences* 104(21):8897-8901













Controls



+Ethinylestradiol



Keywords to remember and understand

- What is meant by the "mechanism of action" (or "mode of action") in toxicology?
- Why is it necessary to understand MoAs? What is the AOP concept?
- What is toxicokinetics? What is ADME?
- What is toxicodynamics?
- What is the relationship between the exposure and the effect?
- What are the different types of toxicity?
- How can the (toxic) effect be measured / assessed?
- What types of "bioassays" are available to study toxicity and/or MoA?
- How is the result (i.e. "toxicity") described in numbers?

